RJA
FPRX

Raymond James & Associates’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Raymond James & Associates’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,465
Closed -$339K – 3398
2016
Q3 		$339K Buy
+6,465
New +$309K ﹤0.01% 2541
2016
Q2 		– Sell
-37,250
Closed -$1.51M – 3112
2016
Q1 		$1.51M Buy
37,250
+2,145
+6% +$73.7K 0.01% 1451
2015
Q4 		$1.46M Buy
+35,105
New +$1.18M 0.01% 1431

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Raymond James & Associates's FPRX Position: Q4 2016 in Review

Raymond James & Associates sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2016, closing a stake of 6,465 shares — an estimated $339K sold.

Raymond James & Associates first reported a position in FPRX in Q4 2015 and held it in 3 quarters. The position peaked at $1.51M in Q1 2016. 172 funds tracked by Wall St. Rank hold FPRX as of Q4 2016.

  • Raymond James & Associates reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Raymond James & Associates sold 6,465 Five Prime Therapeutics, Inc. shares in Q4 2016, an estimated $339K.
  • Raymond James & Associates first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
  • Raymond James & Associates's Five Prime Therapeutics, Inc. position peaked at $1.51M in Q1 2016.
  • 172 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.